Biofrontera Stock Filter Stocks by Fundamentals
| BFRI Stock | USD 0.87 0.01 1.14% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Biofrontera's long-term financial health and intrinsic value.
Biofrontera | Shares Owned by Insiders | Build AI portfolio with Biofrontera Stock |
Biofrontera Institutional Holders
Institutional Holdings refers to the ownership stake in Biofrontera that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Biofrontera's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biofrontera's value.| Shares | Ubs Group Ag | 2025-03-31 | 31.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Scotia Capital Inc | 2025-03-31 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | Aigh Capital Management, Llc | 2025-03-31 | 732.2 K | Rosalind Advisors, Inc. | 2025-03-31 | 644.4 K | Geode Capital Management, Llc | 2025-03-31 | 40.1 K | Citadel Advisors Llc | 2025-03-31 | 28.2 K | Virtu Financial Llc | 2025-03-31 | 18.5 K |
Biofrontera Fundamentals
| Return On Equity | -3.85 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | 11.4 M | ||||
| Shares Outstanding | 9.45 M | ||||
| Shares Owned By Insiders | 13.46 % | ||||
| Shares Owned By Institutions | 26.13 % | ||||
| Number Of Shares Shorted | 182.25 K | ||||
| Price To Book | 17.77 X | ||||
| Price To Sales | 0.22 X | ||||
| Revenue | 37.3 M | ||||
| Gross Profit | 20.24 M | ||||
| EBITDA | (14.44 M) | ||||
| Net Income | (17.76 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 4.92 M | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (10.27 M) | ||||
| Short Ratio | 1.32 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 6.38 | ||||
| Number Of Employees | 92 | ||||
| Beta | 0.3 | ||||
| Market Capitalization | 8.21 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (117.41 M) | ||||
| Working Capital | 8.68 M | ||||
| Net Asset | 22.1 M |
About Biofrontera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biofrontera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofrontera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out Biofrontera Piotroski F Score and Biofrontera Altman Z Score analysis. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 0.085 | Return On Assets | Return On Equity |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.